摘要
The existing efficacy evaluation for coronary heart disease （CHD） angina pectoris does not demonstrate the characteristics and advantages of Chinese medicine （CM）, so a new system of efficacy evaluation which can scientifically and systematically reflect the specific features of CM needs to be urgently set up. Based on wide references of efficacy evaluations of CHD angina pectoris from our country and abroad, and considering the general acceptance by academic circles and demonstration of the characteristics of CM, this paper tries to set up a new index system of efficacy evaluation, combining both disease and syndrome differentiation for CHD angina pectoris. This paper also offers some explorations based on the results of clinical trials. The system is composed of six aspects, including efficacy evaluation of ＂disease＂, syndrome factors and main endpoints （the incidence of important clinical events）, as well as patient reported outcomes, safety evaluation and medical economics.
The existing efficacy evaluation for coronary heart disease （CHD） angina pectoris does not demonstrate the characteristics and advantages of Chinese medicine （CM）, so a new system of efficacy evaluation which can scientifically and systematically reflect the specific features of CM needs to be urgently set up. Based on wide references of efficacy evaluations of CHD angina pectoris from our country and abroad, and considering the general acceptance by academic circles and demonstration of the characteristics of CM, this paper tries to set up a new index system of efficacy evaluation, combining both disease and syndrome differentiation for CHD angina pectoris. This paper also offers some explorations based on the results of clinical trials. The system is composed of six aspects, including efficacy evaluation of ＂disease＂, syndrome factors and main endpoints （the incidence of important clinical events）, as well as patient reported outcomes, safety evaluation and medical economics.
基金
Supported by the National Basic Research Program of China (973 Program,No.2003CB517103)
the Natural Science Foundation of Beijing(No.7062058)
